HK inno.N recently announced on the 4th that it has signed a distribution and co-promotion agreement with Pfizer Korea Pharmaceuticals for the new coronavirus (COVID-19) variant vaccine "Comirnaty L-Peated One Pre-filled Syringe." This is targeted at the national vaccination project for the 2025-2026 seasons.
The vaccine is said by the company to prevent COVID-19 infections caused by the SARS-CoV-2 virus for those aged 12 and older. A single injection of 0.3 ml is administered intramuscularly. It can be administered only after at least three months have passed since the last COVID-19 vaccination.
Kwak Dal-won, the CEO of HK inno.N, noted, "We will contribute to improving public health by ensuring a stable supply of the vaccine." Oh Dong-wook, the CEO of Pfizer Korea Pharmaceuticals, said, "In particular, we will protect high-risk groups such as those aged 65 and older and immunocompromised individuals."